| Citation: |
LIU Weikang, CHEN Yiran, YANG Yinmo. Perioperative Hot Issues and Management Strategies for Pancreatic Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 740-746. DOI: 10.12290/xhyxzz.2024-0407
|
Pancreatic cancer is characterized by high malignancy, low early diagnosis rates, and poor prognosis. Approximately 15%-20% of patients at initial diagnosis have resectable pancreatic cancer, 20%-30% have borderline resectable pancreatic cancer, and over 50% are present with unresectable. Surgical resection remains the only potentially curative treatment option available, but the unique anatomical position of the pancreatic head necessitates complex gastrointestinal reconstruction after resection, which may lead to severe complications such as grade B/C pancreatic fistulas and bleeding. Comprehensive preoperative preparation and individualized postoperative management are crucial to reducing perioperative complications, enhancing patient quality of life, and expediting the initiation of adjuvant therapy. This article reviews perioperative integrated management strategies for patients with pancreatic cancer, drawing on literature and our center's experience, including nutritional therapy, psychological support, preoperative jaundice reduction, neoadjuvant treatment, the prevention and management of pancreatic fistulas and postoperative bleeding, with the aim of improving clinical outcomes and overall survival rates.
| [1] |
Siegel R L, Giaquinto A N, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820
|
| [2] |
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035
Zheng R S, Chen R, Han B F, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035
|
| [3] |
Liu W K, Tang B J, Wang F, et al. Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China[J]. Am J Cancer Res, 2021, 11(6): 3055-3069.
|
| [4] |
Bicakli D H, Uslu R, Güney S C, et al. The relationship between nutritional status, performance status, and survival among pancreatic cancer patients[J]. Nutr Cancer, 2020, 72(2): 202-208. DOI: 10.1080/01635581.2019.1634217
|
| [5] |
Hendifar A E, Petzel M Q B, Zimmers T A, et al. Pancreas cancer-associated weight loss[J]. Oncologist, 2019, 24(5): 691-701. DOI: 10.1634/theoncologist.2018-0266
|
| [6] |
Xu J Y, Tian X D, Song J H, et al. Preoperative nutrition support may reduce the prevalence of postoperative pancreatic fistula after open pancreaticoduodenectomy in patients with high nutritional risk determined by NRS2002[J]. Biomed Res Int, 2021, 2021: 6691966.
|
| [7] |
Jabłońska B, Pawlicki K, Mrowiec S. Associations between nutritional and immune status and clinicopathologic factors in patients with pancreatic cancer: a comprehensive analysis[J]. Cancers (Basel), 2021, 13(20): 5041. DOI: 10.3390/cancers13205041
|
| [8] |
Tsukagoshi M, Harimoto N, Araki K, et al. Impact of preoperative nutritional support and rehabilitation therapy in patients undergoing pancreaticoduodenectomy[J]. Int J Clin Oncol, 2021, 26(9): 1698-1706. DOI: 10.1007/s10147-021-01958-0
|
| [9] |
Aoyama T, Maezawa Y, Hashimoto I, et al. Clinical impact of nutrition and inflammation assessment tools in pancreatic cancer treatment[J]. Anticancer Res, 2023, 43(9): 3849-3860. DOI: 10.21873/anticanres.16572
|
| [10] |
Jamieson N B, Denley S M, Logue J, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2011, 18(8): 2318-2328. DOI: 10.1245/s10434-011-1560-3
|
| [11] |
Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer[J]. Br J Surg, 2011, 98(2): 268-274.
|
| [12] |
Ikeguchi M, Hanaki T, Endo K, et al. C-reactive protein/albumin ratio and prognostic nutritional index are strong prognostic indicators of survival in resected pancreatic ductal adenocarcinoma[J]. J Pancreat Cancer, 2017, 3(1): 31-36. DOI: 10.1089/pancan.2017.0006
|
| [13] |
Massie M J. Prevalence of depression in patients with cancer[J]. J Natl Cancer Inst Monogr, 2004, 2004(32): 57-71. DOI: 10.1093/jncimonographs/lgh014
|
| [14] |
Boyd C A, Benarroch-Gampel J, Sheffield K M, et al. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma[J]. Surgery, 2012, 152(3): 403-413. DOI: 10.1016/j.surg.2012.06.010
|
| [15] |
Seoud T, Syed A, Carleton N, et al. Depression before and after a diagnosis of pancreatic cancer: results from a national, population-based study[J]. Pancreas, 2020, 49(8): 1117-1122. DOI: 10.1097/MPA.0000000000001635
|
| [16] |
Chen G F, Yu W D, Wang J R, et al. The methods of preoperative biliary drainage for resectable hilar cholangiocarcinoma patients: a protocol for systematic review and meta analysis[J]. Medicine (Baltimore), 2020, 99(21): e20237. DOI: 10.1097/MD.0000000000020237
|
| [17] |
Fujii T, Yamada S, Suenaga M, et al. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospec-tive observational study[J]. Pancreas, 2015, 44(3): 465-470. DOI: 10.1097/MPA.0000000000000265
|
| [18] |
Shen Z Y, Zhang J, Chen H D, et al. Does pre-operative biliary drainage influence long-term survival in patients with obstructive jaundice with resectable pancreatic head cancer?[J]. Front Oncol, 2020, 10: 575316. DOI: 10.3389/fonc.2020.575316
|
| [19] |
Lu B, Chen Y, Qin S Y, et al. Value of preoperative biliary drainage in pancreatic head cancer patients with severe obstructive jaundice: a multicenter retrospective study[J]. Saudi J Gastroenterol, 2024, 30(3): 154-161. DOI: 10.4103/sjg.sjg_296_23
|
| [20] |
Versteijne E, Van Dam J L, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40(11): 1220-1230. DOI: 10.1200/JCO.21.02233
|
| [21] |
Van Dam J L, Janssen Q P, Besselink M G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials[J]. Eur J Cancer, 2022, 160: 140-149. DOI: 10.1016/j.ejca.2021.10.023
|
| [22] |
Van Dongen J C, Suker M, Versteijne E, et al. Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC trial)[J]. Ann Surg, 2022, 275(5): 979-984. DOI: 10.1097/SLA.0000000000004313
|
| [23] |
Labori K J, Bratlie S O, Andersson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancrea-tic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2024, 9(3): 205-217. DOI: 10.1016/S2468-1253(23)00405-3
|
| [24] |
Doshi S, Abad J, Wells A, et al. Weight loss during neoadjuvant chemotherapy impacts perioperative outcomes in patients undergoing surgery for pancreatic cancer[J]. Pancreatology, 2023, 23(8): 1020-1027. DOI: 10.1016/j.pan.2023.10.006
|
| [25] |
Pulvirenti A, Marchegiani G, Pea A, et al. Clinical implications of the 2016 international study group on pancreatic surgery definition and grading of postoperative pancreatic fistula on 775 consecutive pancreatic resections[J]. Ann Surg, 2018, 268(6): 1069-1075. DOI: 10.1097/SLA.0000000000002362
|
| [26] |
Mungroop T H, Van Rijssen L B, Van Klaveren D, et al. Alternative fistula risk score for pancreatoduodenectomy (a-FRS): design and international external validation[J]. Ann Surg, 2019, 269(5): 937-943. DOI: 10.1097/SLA.0000000000002620
|
| [27] |
Mungroop T H, Klompmaker S, Wellner U F, et al. Updated alternative fistula risk score (ua-FRS) to include minimally invasive pancreatoduodenectomy: Pan-European validation[J]. Ann Surg, 2021, 273(2): 334-340. DOI: 10.1097/SLA.0000000000003234
|
| [28] |
Schindl M, Függer R, Götzinger P, et al. Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy[J]. Br J Surg, 2018, 105(7): 811-819. DOI: 10.1002/bjs.10840
|
| [29] |
Oweira H, Mazotta A, Mehrabi A, et al. Using a reinforced stapler decreases the incidence of postoperative pancreatic fistula after distal pancreatectomy: a systematic review and meta-analysis[J]. World J Surg, 2022, 46(8): 1969-1979. DOI: 10.1007/s00268-022-06572-3
|
| [30] |
Diener M K, Seiler C M, Rossion I, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial[J]. Lancet, 2011, 377(9776): 1514-1522. DOI: 10.1016/S0140-6736(11)60237-7
|
| [31] |
Bassi C, Molinari E, Malleo G, et al. Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial[J]. Ann Surg, 2010, 252(2): 207-214. DOI: 10.1097/SLA.0b013e3181e61e88
|
| [32] |
Lyu Y X, Cheng Y X, Wang B, et al. Peritoneal drainage or no drainage after pancreaticoduodenectomy and/or distal pancreatectomy: a meta-analysis and systematic review[J]. Surg Endosc, 2020, 34(11): 4991-5005. DOI: 10.1007/s00464-019-07293-w
|
| [33] |
Dai M H, Liu Q F, Xing C, et al. Early drain removal is safe in patients with low or intermediate risk of pancreatic fistula after pancreaticoduodenectomy: a multicenter, randomized controlled trial[J]. Ann Surg, 2022, 275(2): e307-e314. DOI: 10.1097/SLA.0000000000004992
|
| [34] |
Chen K, Liu Z H, Yang B H, et al. Efficacy and safety of early drain removal following pancreatic resections: a meta-analysis[J]. HPB (Oxford), 2023, 25(5): 485-496. DOI: 10.1016/j.hpb.2023.02.005
|
| [35] |
Uggeri F, Nespoli L, Sandini M, et al. Analysis of risk factors for hemorrhage and related outcome after pancreatoduodenectomy in an intermediate-volume center[J]. Updates Surg, 2019, 71(4): 659-667. DOI: 10.1007/s13304-019-00673-w
|
| [36] |
Brodie B, Kocher H M. Systematic review of the incidence, presentation and management of gastroduodenal artery pseudoaneurysm after pancreatic resection[J]. BJS Open, 2019, 3(6): 735-742. DOI: 10.1002/bjs5.50210
|
| [37] |
Treckmann J, Paul A, Sotiropoulos G C, et al. Sentinel bleeding after pancreaticoduodenectomy: a disregarded sign[J]. J Gastrointest Surg, 2008, 12(2): 313-318. DOI: 10.1007/s11605-007-0361-2
|
| [38] |
Preston W A, Collins M L, Gönen M, et al. Hemorrhage sites and mitigation strategies after pancreaticoduodenectomy[J]. JAMA Surg, 2024, 22: e241228. DOI: 10.1001/jamasurg.2024.1228.
|
| [39] |
Wu X, Chen G, Wu W M, et al. Management of late hemorrhage after pancreatic surgery: treatment strategy and prognosis[J]. J Int Med Res, 2020, 48(6): 300060520929127.
|
| 1. |
朱静静，尚琴芬. 病态肥胖症患者脑出血术后困难气道1例的护理. 中国乡村医药. 2024(02): 65-67 .
| |
| 2. |
董麦娟，袁伟，邢静瑶，王强. 罗哌卡因联合右美托咪定竖脊肌阻滞在减重手术中的镇痛效果观察. 重庆医学. 2023(02): 210-214 .
| |
| 3. |
阮俊杰，李远，谢磊，姜华. 喉罩全身麻醉用于软骨发育不全的青少年四肢矫形手术的临床观察. 北京医学. 2023(03): 226-231 .
| |
| 4. |
徐胜勇，徐军，朱华栋，于学忠. 加强困难气道管理 提升临床救治水平——《2022年美国麻醉医师协会困难气道管理实践指南》解读. 协和医学杂志. 2022(03): 427-432 .
本站查看
| |
| 5. |
伍娜，黄春芬，谢俊玲. 1例困难气道并多重耐药菌感染气管切开患者的护理. 中国当代医药. 2022(25): 159-162 .
| |
| 6. |
温蔡英，洪晓玲，温玉英. 硬膜外舒芬太尼联合罗哌卡因麻醉对减轻瘢痕子宫产妇择期剖宫产术内脏疼痛的影响研究. 实用妇科内分泌电子杂志. 2022(26): 29-33 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: